Teva Pharma (TEVA): 3 Key Points From Analyst Event - Jefferies

September 12, 2016 7:41 AM EDT
Get Alerts TEVA Hot Sheet
Price: $34.10 --0%

Rating Summary:
    19 Buy, 20 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 23 | Down: 31 | New: 34
Trade TEVA Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Teva Pharma (NYSE: TEVA) after the company hosted a 2.5+ hour event Friday with the investment community, providing updates on the combined generics businesses following the completion of the $40.5B AGN transaction last month. Mgt believes that they are well positioned for growth driven by the deepest pipeline in the industry with 320 ANDAs on file at the FDA and 325 products in development targeting a massive $200B in innovator sales. Key takeaways include:

1) While consensus forecasts project low single digit growth ahead for TEVA’s US generics business, mgt continues to believe that they can generate 5% annual topline growth (~10% growth from new products offset by ~5% base erosion).

2) Mgt believes that they are well positioned globally to benefit from growth of the middle class and an aging population – particularly in what the co terms as “growth markets” (AsiaPacific/Japan, Russia/CE Europe, Latin America) representing a population of 6B people and 50% of global GDP.

3) Mgt confirmed that it still has two gAdvair programs in development following the merger with AGN. And while declining to comment on specifics relating to the development programs, mgt indicated its optimism in filing sometime in 2017.

No change to the price target of $69.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $50.21 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Management Comments

Related Entities

Jefferies & Co, Definitive Agreement

Add Your Comment